KenLee

Associate

Singapore + 65.6233.5507

Connect:

Share

Ken Lee practices in the areas of private equity and mergers and acquisitions. He has assisted in advising clients on a range of corporate transactions, including investments, spin-offs, acquisitions, and fund formations. Ken also has experience advising clients on their day-to-day business needs such as commercial agreements and ongoing Singapore regulatory obligations.

Prior to joining Jones Day in 2019, Ken practiced at a global law firm where he advised clients on public and private M&A transactions and on corporate actions for Singapore Exchange Limited (SGX) listed entities.

Experience

  • Valmet acquires process gas chromatography business of Siemens AGJones Day advised Valmet Oyj in the €102.5 million acquisition of the process gas chromatography business of Siemens AG.
  • Affiliate of Centre Lane Partners acquires appliance business from Instant BrandsJones Day advised an affiliate of Centre Lane Partners in the acquisition and financing of the appliances business of Instant Brands, designer and distributor of kitchen and home appliances, including the Instant Pot, pursuant to Section 363 of title 11 of the United States Code.
  • Twilio sells ValueFirst to TanlaJones Day advised Twilio Inc. in the sale of ValueFirst Digital Media Private Limited to Tanla Platforms Limited, a company based in India with shares listed on BSE Limited and the National Stock Exchange of India.
  • Maxeon Solar Technologies completes public offering of $241.2 million of Ordinary Shares and concurrent private placement of $42 million of Ordinary SharesJones Day represented Maxeon Solar Technologies, Ltd., one of the world’s leading global manufacturers and marketers of premium solar power technology, in a public offering of 8,613,500 Ordinary Shares, consisting of 5,620,000 Ordinary Shares offered by Maxeon and 2,993,500 Ordinary Shares offered by an affiliate of TotalEnergies SE, one of Maxeon’s existing shareholders.
  • Junshi Biosciences forms joint venture with Rxilient Biotech to develop and commercialize toripalimab in Southeast AsiaJones Day advised Junshi Biosciences in the formation of a joint venture company, Excellmab, with Rxilient Biotech to develop and commercialize toripalimab, an anti-PD-1 monoclonal antibody drug, in nine Southeast Asian countries.
  • UPL Ltd announces strategic corporate realignmentJones Day advised UPL Limited in its corporate restructuring of the UPL Group to better align different business units by creating "distinct pure-play platforms" under various subsidiaries.
  • Stonepeak forms strategic logistics investment partnership with EqualbaseJones Day represented Stonepeak, a leading U.S.-based alternative investment firm specializing in infrastructure and real assets, in connection with the formation of a Pan-Asia logistics real estate platform in partnership with Equalbase, a development, project, and asset manager specializing in industrial real estate assets in Asia.
    • View All

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.